Moleculin Biotech, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -20.1% | -20.1% | -18.9% |
| FY2022 | -55.6% | -55.6% | -50.5% |
| FY2023 | -96.3% | -96.3% | -77.9% |
| FY2024 | -232.4% | -232.4% | -153.9% |
| FY2025 | -223.6% | -223.6% | -151.7% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -20.1% | -20.1% | -18.9% |
| FY2022 | -55.6% | -55.6% | -50.5% |
| FY2023 | -96.3% | -96.3% | -77.9% |
| FY2024 | -232.4% | -232.4% | -153.9% |
| FY2025 | -223.6% | -223.6% | -151.7% |